Integrated BioPharma (INBP) AI Stock Analysis

• Market Cap: $8.42M
• Dividend Yield: N/A
• Average Volume (3M): 8.66K
• Price to Earnings (P/E): 6.9
• Beta (1Y): 0.42
• Revenue Growth: 4.67%
• EPS Growth: N/A
• Country: US
• Employees: 147
• Sector: Consumer Defensive
• Sector Strength: 46
• Industry: Packaged Foods
• EPS (TTM): 0.02
• Shares Outstanding: 30,300,720
• 10 Day Avg. Volume: 4,446
• 30 Day Avg. Volume: 8,664
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: 0.14
• Enterprise Value/Gross Profit: 1.39
• Enterprise Value/Ebitda: 2.43
• 1Y Price Target: $0.50
• Price Target Upside: 78.57% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 73 Outperform
• Price Target: $0.50 ▲(78.57% Upside)

Integrated BioPharma's strong financial stability, highlighted by its robust cash flow and low leverage, is the most significant strength. However, this is somewhat offset by bearish technical indicators, indicating short-term challenges. Valuation metrics suggest potential undervaluation, supporting a positive long-term outlook.

Integrated BioPharma Business Overview & Revenue Model

Company Description

Integrated BioPharma, Inc. (INBP) operates in the pharmaceutical and nutraceutical sectors, focusing on the development, manufacturing, and distribution of health and wellness products. The company's core offerings include a range of nutritional supplements, herbal products, and related health products, targeting both domestic and international markets. Integrated BioPharma leverages its expertise in biotechnology and pharmaceuticals to deliver high-quality products aimed at improving consumer health and wellness.

How the Company Makes Money

Integrated BioPharma primarily generates revenue through the sale of its nutraceutical and pharmaceutical products. The company has established a diverse revenue model, which includes direct sales to consumers, distribution through retail partners, and partnerships with major health and wellness brands. Additionally, Integrated BioPharma engages in contract manufacturing, producing private-label products for other companies, thus diversifying its income streams. The company’s revenue is further supported by strategic collaborations and partnerships that enhance its market reach and operational efficiency.

Integrated BioPharma Financial Statement Overview

Summary

Integrated BioPharma exhibits strong financial stability with a low debt-to-equity ratio and robust cash flow trends. However, declining revenue and moderate profitability metrics indicate challenges. The solid balance sheet and cash flow offer a foundation for growth.

Income Statement

Integrated BioPharma's income statement shows a declining revenue trend from 2021 to 2024, with a recent TTM revenue of $52.93M, down from $53.17M annually. The company's gross profit margin stands at 9.59%, and a net profit margin of 1.75% for TTM indicates modest profitability, although improved from previous years. The EBIT margin of 2.74% and EBITDA margin of 3.34% demonstrate operational efficiency improvement over the past reporting periods. However, the decline in revenue growth presents a concern.

Balance Sheet

The balance sheet reflects strong financial health with a debt-to-equity ratio of 0.07, indicating low leverage. The equity ratio of 76.89% in the TTM period shows a strong equity base relative to assets. Return on equity is modest at 4.71%, suggesting limited profitability relative to equity. The company's stable equity position and low debt enhance its financial stability, though ROE could be improved.

Cash Flow

Cash flow analysis shows positive trends with a free cash flow growth rate of 345.64% from the previous annual report to the TTM. The operating cash flow to net income ratio is 2.49, and the free cash flow to net income ratio is 1.87, indicating strong cash conversion from profits. Consistent free cash flow generation supports operational sustainability and investment capabilities.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	50.32M	50.67M	56.25M	63.56M	52.77M
Gross Profit	3.88M	4.06M	6.55M	9.48M	6.73M
EBITDA	1.54M	1.27M	3.56M	8.33M	4.26M
Net Income	112.00K	-34.00K	3.84M	8.01M	4.11M
Balance Sheet
Total Assets	26.21M	25.43M	25.25M	25.44M	22.94M
Cash, Cash Equivalents and Short-Term Investments	1.68M	1.32M	331.00K	210.00K	402.00K
Total Debt	1.80M	2.67M	2.06M	6.00M	11.13M
Total Liabilities	6.97M	6.57M	6.67M	11.11M	16.88M
Stockholders Equity	19.24M	18.86M	18.57M	14.33M	6.07M
Cash Flow
Free Cash Flow	390.00K	1.12M	3.60M	2.75M	1.13M
Operating Cash Flow	943.00K	1.23M	4.09M	3.05M	1.34M
Investing Cash Flow	-553.00K	-111.00K	-465.00K	-199.00K	-110.00K
Financing Cash Flow	-29.00K	-136.00K	-3.50M	-3.04M	-1.30M

Integrated BioPharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBP, the sentiment is Neutral. The current price of 0.28 is above the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.30, and below the 200-day MA of 0.31, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.08 is Neutral, neither overbought nor oversold. The STOCH value of 32.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for INBP.

Integrated BioPharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATR	80 Outperform	$290.99M	22.12	9.15%	―	4.33%	-6.33%
FTLF	75 Outperform	$173.08M	22.54	21.88%	―	3.91%	-1.39%
INBP	73 Outperform	$8.42M	6.90	6.38%	―	4.67%	―
USNA	70 Outperform	$579.22M	17.59	6.54%	―	2.75%	-37.25%
HLF	63 Neutral	$951.67M	2.90	-31.74%	―	-2.25%	288.79%
Sector *	63 Neutral	$20.46B	14.47	-3.60%	3.13%	2.63%	-6.18%
NAII	53 Neutral	$22.68M	―	-10.25%	―	-1.16%	-146.23%

Integrated BioPharma Corporate Events

Integrated BioPharma Secures New Credit Line with PNC

On April 15, 2025, Integrated BioPharma, Inc. and its subsidiary, Manhattan Drug Company, entered into a Loan Agreement with PNC Bank, securing a revolving line of credit of up to $4 million and a Convertible Equipment Line of Credit of up to $500,000. This agreement, which includes a security interest in the company’s assets, aims to support the purchase of equipment and vehicles. Concurrently, Integrated BioPharma and its associated entities settled their previous credit and loan agreement with PNC Bank, paying off the outstanding balance and terminating the prior arrangement, marking a strategic financial restructuring.